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Abstract 50 
Background: Meningiomas are the most frequent primary brain tumors of the central nervous system. 51 
The standard of treatment is surgery and radiotherapy, but effective pharmacological options are not 52 
available yet. The well-characterised genetic background stratifies these tumors in several subgroups, 53 
thus increasing diversification. We identified EGFR-STAT1 overexpression and activation as a common 54 
identifier of these tumors. 55 
Methods: We analysed STAT1 overexpression and phosphorylation in 131 meningiomas of different 56 
grades and locations by utilising several techniques, including Western blots, qPCR and 57 
immunocytochemistry.  We also silenced and overexpressed wild-type and mutant forms of the gene 58 
to assess its biological function and its network. Results were further validated by drug testing. 59 
Results: STAT1 was found widely overexpressed in meningioma but not in the corresponding healthy 60 
controls. The protein showed a constitutive phosphorylation not dependent on the JAK/STAT pathway.  61 
STAT1 knock-down resulted in a significant reduction of cellular proliferation and deactivation of AKT 62 
and ERK1/2. STAT1 is known to be activated by EGFR, so we investigated the tyrosine kinase and 63 
found that EGFR was also constitutively phosphorylated in meningioma and was responsible for the 64 
aberrant phosphorylation of STAT1. The pharmaceutical inhibition of EGFR caused a significant 65 
reduction in cellular proliferation and of overall levels of Cyclin D1, pAKT and pERK1/2.   66 
Conclusions: STAT1 EGFR-dependent constitutive phosphorylation is responsible for a positive 67 
feedback loop that causes its own overexpression and consequently an increased proliferation of the 68 
tumor cells. These findings provide the rationale for further studies aiming to identify effective 69 
therapeutic options in meningioma. 70 
 71 
 72 
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Importance of the Study 77 
Meningioma accounts for 37% of primary brain tumors. This year in the United States an estimated 78 
thirty-two thousand people will be diagnosed with meningioma. Despite the majority of tThese tumors 79 
are benign in nature, they can cause mild to severe morbidity and even WHO grade I eventually 80 
progress tocan have a more aggressive phenotypeclinical course. Therapeutic options are still limited 81 
to surgical resection and radiotherapy since more effort is needed to decipher the communal molecular 82 
mechanisms that define meningiomas despite their genetic background.  83 
Aiming to discover novel therapeutic targets, we identified STAT1 as aberrantly overexpressed and 84 
constitutively activated in most of the meningioma examined. Its activation is dependent on the 85 
constitutive phosphorylation of EGFR and leads to an increased proliferation of tumor cells. We show 86 
that specific EGFR inhibition can reduce tumor cell proliferation and we show evidence why previous 87 
trials failed. Therfore, we suggest that this therapeutic strategy be re-evaluated.  88 
 89 
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Introduction 91 
Meningiomas are the most common primary brain tumors, classified meningiomas as Grade I (~80%), 92 
atypical Grade II (15-20%) and anaplastic/malignant Grade III (1-3%). Surgery is the primary choice of 93 
treatment; complete resection may be curative but it can be achieved only for permissive locations1. 94 
The genetic background of meningioma is well characterised, with inactivation/deletion of NF2 found in 95 
~60% of sporadic meningiomas2.  96 
Previously, we identified phosphorylated Signal Transducer and Activator of Transcription 1 (STAT1) 97 
as overexpressed in the grade I meningioma cell line 3 and phosphorylated STAT1 in meningioma tissue 98 
of all grades4. In addition, we identified phosphorylation of STAT3 among remaining STAT family 99 
members3,4. STAT1 belongs to the STAT protein family that comprise seven members (STAT1-4, 100 
STAT5A, STAT5B and STAT6), and it can be phosphorylated on the tyrosine 701 (Y701) and the serine 101 
727 (S727)5,6. STATs are essential components of the evolutionarily conserved JAK/STAT signalling 102 
pathway4,7 that plays a role in immune response8,9 and its dysregulation is linked to cancer10,11. This 103 
canonical pathway is activated by ligands including interferons, interleukins and some growth factors, 104 
binding to their receptors thus inducing phosphorylation of the JAKs (Janus Kinases), leading to to 105 
tyrosine-STAT phosphorylation by JAKs4,6. In addition STATs can alsos be phosphorylated by receptor 106 
tyrosine kinases and cytoplasmic non-receptor tyrosine kinases5. Phosphorylated STATs homo- and 107 
hetero-dimerize entering the nucleus to regulate transcription of target genes6,12. JAKs include JAK1-3 108 
and TYK2. JAK1 and JAK2 are phosphorylated following type-II interferon (IFN) stimulation, while 109 
JAK1 and TYK2 are activated in type-I interferon signalling (IFNα, IFNβ; etc.)4-6. Activated JAK/STAT 110 
pathway can be quenched by the SOCSs (Suppressors Of Cytokine Signalling), the PIASs (Protein 111 
Inhibitors of Activated STAT) and the PTPs (Protein Tyrosine Phosphatases)5 112 
Activated STAT1 acts as a transcriptional regulator, controlling its own transcription as well as the 113 
expression of several IFN-regulated genes (IRGs)13,14. STAT1 was considered a tumor suppressor as 114 
its expression correlated with good prognosis in several types of cancer15-18. However, other studies 115 
established a pro-tumorigenic role of STAT1, which correlated with its overexpression and activation19. 116 
Due to its function in sensing and regulating cytokine production, STAT1 exerts a role in promoting an 117 
immunosuppressive tumor environment19,20. Hence, the overall role of STAT1 in cancer remains 118 
complex suggesting that its function is most likely cancer type-dependent.  119 
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In the present study, we identified STAT1 as overexpressed and phosphorylated in meningioma 120 
compared to normal and we show that its overexpression correlates with an increased proliferation of 121 
the tumor cells as well as an activation of AKT and ERK1/2. We demonstrate that STAT1 122 
overexpression and phosphorylation is not dependent on the JAK/STAT pathway but it depends on a 123 
positive feedback loop caused by the constitutive activation of the Epidermal Growth Factor Receptor 124 
(EGFR). The pharmaceutical inhibition of EGFR in meningioma caused the deactivation of STAT1 and 125 
other cancer-related pathways, eventually leading to a significant reduction in cellullar proliferation. 126 
Our findings underline a crucial role of the EGFR and STAT1 signalling in the pathology of meningiomas 127 
and point to a therapeutic potential of its inhibition. 128 
 129 
Materials and Methods 130 
Meningioma specimens, tumor digestion and primary meningioma cultures 131 
Meningioma specimens were collected following the ethical approvals (REC: 14/SW/0119; IRAS project 132 
ID: 153351; Plymouth Hospitals NHS Trust: R&D: 14/P/056, North Bristol NHS Trust: R&D: 3458) 133 
received a unique MN number. J specimens were collected via UK-Brain-Archive Information-Network 134 
(BRAIN UK; Ref.:15/011; REC: 14/SC/0098) (Supplementary Table 1). Normal meningeal tissue (NMT) 135 
was purchased from Analytical Biological Service Inc. 136 
Primary cells were generated from 36 fresh tTumor tissues. Tissue were disaggregated in DMEM with 137 
15% FBS, 100 U/ml penicillin/streptomycin and 20 U/ml Collagenase III (Worthington Biochemical Corp) 138 
for 2 h at 37 C; after cells were pelleted at 1000 rpm for 5 min, resuspended and seeded (modified 139 
from21). MN cells were cultured in DMEM at 37 C in 5% CO2. HMC cells (Caltag Medsystems Ltd) 140 
were grown in the recommended medium at 37 C in 5% CO2. Cells were kept on average 4-5 141 
passages. 142 
Normal human meningeal cell were purchased from ScienceCell (UK distributor: Caltag Medsystems; 143 
Catalog#1400), U251 glioma cells were purchased from ECACC (Cat n.: 09063001), an immortalized 144 
grade 1 meningioma cell line  BM-1 were (DSMZ; Cat.n.: ACC 599) and authenticated via genomic 145 
fingerprinting (Eurofins Genomics Europe Applied Genomics GmbH).  146 
Western blotting, immunofluorescence and immunohistochemistry 147 
Western blots (WB) from 26 frozen tissues and cell cultures were performed as previously described3. 148 
All primary antibodies used are listed in Supplementary Table 12. Immunoreactive bands were 149 
quantified using Scion Image software and each band was normalized vs. the corresponding GAPDH. 150 
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Immunofluorescence of 38 paraffin embedded tissue was performed as previously described3. Confocal 151 
microscopy was executed using a Leica DMI6000B; Z-stack micrographs were taken using the 40X or 152 
63X objectives. Immunofluorescent images for STAT1-silencing studies were taken with the Olympus 153 
CKX41 with the 20X objective; images were processed with the QCapture Pro 6.0 software. 154 
For immunohistochemistry, paraffin sections (4μm) were processed as described22. Avidin-biotin 155 
blocking solution was used with EDTA pretreatment. Sections were incubated with appropriate biotin-156 
labelled secondary antibody and with horseradish peroxidase for detection using Vectashield Elite 157 
(Vector Laboratories UK) according to the manufacturer’s protocol. As a control, sections were 158 
incubated with omission of the primary antibody.  159 
Results were reviewed ‘blind’ to the histological grade by a neuropathologist (DAH). Semiquantitaive 160 
assessment of the intensity of immunoreactivity was undertaken and scored as follow: 0 none; 1 weak; 161 
2 moderate; 3 strong. 162 
RNA isolation and gene expression analysis 163 
Total RNA was extracted from 95 frozen tissues and cells using the Qiazol® reagent (Qiagen UK), 164 
following manufacturer’s protocol. The quality, integrity and concentration of RNA were established 165 
using the NanoDrop ND-2000 (ThermoFisher Scientific UK). 166 
Real-Time PCR (qPCR) was conducted using 50 ng/well employing the EXPRESS One-Step SYBR® 167 
GreenERTM kit (Invitrogen) on a LightCycler® 480 System (Roche Diagnostics, Switzerland), following 168 
manufacturer’s protocol (primers annealing temperature= 58 °C). Primers used were: PrimePCR™ 169 
SYBR® Green Assay STAT1 (BioRad), hGAPDH (2 µM, Invitrogen- Forward: 5’-170 
GAGAAGGCTGGGGCTCATTT-3’; Reverse 5’-AGTGATGGCATGGACTGTGG-3’). Relative gene 171 
expression analysis of STAT1 and GAPDH was calculated using the 2-ΔΔCt method23, employing the 172 
HMC as calibrator. 173 
STAT1 silencing and overexpression 174 
Stat1 shRNA Lentiviral Particles (Santa Cruz Biotechnology, sc-44123-V), containing 3 target-specific 175 
constructs that encode 19-25nt (plus hairpin) or scramble shRNA control (Santa Cruz Biotechnology, 176 
sc-108080), were added onto the cells in media containing protamine sulfate salt (8 μg/ ml) (Sigma). 177 
Cells were infected for 48 h before applying puromycin (5 μg/ml) for 3 days. 178 
STAT1-WT gene was cloned into pCDNA3.1+ in a two-step process using the following primers: 179 
STAT1-F1 (5’-AAAGCTAGCGGCCGGCCATGTCTCAG-3’), STAT1-R1 (5’-180 
CGTCTCGAGGTCAATTACCAAACCAGGCT-3’) for the first part; STAT1-2F (5’-181 
GACCTCGAGACGACCTCTCT), STAT1-2R (5’-AGTGTTTAAACTTAATTAACTATACTGTGTTCA-3’) 182 
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for the second part. The 551 bp long STAT1 part in between the restriction sites HindIII and EcoRI was 183 
synthesised (GeneArt, ThermoFisher Scientific) to generate the following mutations: Y701F, S727E and 184 
Y701F/S727E; each one was cloned into pCDNA-STAT1-WT to replace the wild-type part. All 185 
generated plasmids were sequenced before further use (Eurofins). U251-MG cells were transfected 186 
and selected as previously described 24. 187 
Ki-67 staining and Proliferation assay 188 
For Ki-67 staining, cells were grown on chamber slides, lentivirus-transfected and stained as previously 189 
described3.  190 
For U251-MG proliferation assay, the pool of U251-MG selected cells, transfected with pCDNA, STAT1-191 
WT and the three mutants, were seeded at 1000 cell/well in 96 well plates and proliferation was 192 
determined after 24, 48 and 72 h using the ‘CellTiter-Glo® Luminescent Cell Viability Assay’ as 193 
recommended by the supplier (Promega).  194 
For drug testing, meningioma cells (3000 cell/well) were plated in 96-well culture plates and allowed 195 
to proliferate for 24 h. Cell proliferation was calculated as percentage of control cells. Graphs were 196 
generated using GraphPad Prism 5.  197 
Flow cytometry analysis 198 
Confluent meningioma cells were resuspended in ice-cold staining buffer (PBS, 2%FBS) at a final 199 
concentration of 1x105 cells. Cells were stained for 30 min at RT in the dark with the following: CD45-200 
FITC, HLA-DR-PE, CD14-PerCP5.5 and CD44 –APC (Becton Dickinson Biosciences, Pharmigen), 201 
washed twice with 2 ml of staining buffer and centrifuged at 1500 rpm for 5 min at 4°C . The relevant 202 
single isotype controls were used. Data acquisition was collected on 1x104 cells on a Accuri  flow 203 
cytometer (BD Biosciences) and analysis was performed using the Flow Jo software v10.0  (FlowJo 204 
LLC, Ashland, OR). 205 
Statistical analysis 206 
Probability (p) values were calculated using the Student’s t-Test or the ANOVA one-way analysis of 207 
variance, using GraphPad Prism 5.01 and MS Excel 2016 software. P values <0.05 were considered 208 
statistically significant. The results are expressed as means ± SD or ± SEM. 209 
 210 
 211 
 212 
Formatted: Indent: First line:  0"
NOA-D-19-00065R2 
9 
 
 213 
 214 
Results 215 
STAT1 is overexpressed and aberrantly activated in meningioma 216 
 217 
We analysed STAT1 expression in meningioma tumors compared to normal meninges (NMT). In all 218 
cases STAT1 was overexpressed and in most of the cases, we detected high levels of  phosphorylated 219 
STAT1 (Y701 and S727) (representative Western blot of Fig. 1A and qPCR of Fig. 1C). 220 
Immunohistochemical studies validated STAT1 overexpression in all meningioma samples (Fig. 1B); 221 
also pSTAT1-Y701 and -S727 showed higher staining compared to normal meninges and an increasing 222 
score throughout the grades. As control, we further analysed STAT1 and pSTAT1 abundance in two 223 
additional normal meninges and a normal brain (Fig. 1D).  224 
Then, we examined STAT1 expression and phosphorylation in meningioma-derived primary cells (MN) 225 
and in BM-125 compared to HMC. MN cells were used between passage 3 and 5 and no B/T 226 
lymphocytes or infiltrating macrophages were detected (Supplementary Fig. 1A). All cells were  227 
vimentin-positive26 and CD90-negative, suggesting no fibroblasts contamination27 (Supplementary Fig. 228 
1B). STAT1 was found overexpressed in BM-1 and MNs compared to HMC and both pSTAT1-Y701 229 
and -S727 were present across all samples while faint and undetectable in HMC (Fig. 1C). Q-PCR 230 
analysis confirmed that STAT1 expression was higher in most of the MNs and in BM-1 compared to 231 
control (Fig. 1F). Of note, STAT1 overexpression was independent of Merlin status (Supplementary Fig. 232 
1C, D).  233 
Furthermore, pSTAT1-Y701 showed a cytoplasmic localization while pSTAT1-S727 was nuclear (Fig. 234 
1B), in agreement with the immunofluorescent staining of primary MN cells (Fig. 1G). 235 
Overall, we examined 131 meningiomas vs. 10 normal meninges and 5 normal brains and we 236 
demonstrate substantial overexpression of STAT1 in 100 of them with a variety of methods 237 
(Supplementary Table 12). 238 
 239 
STAT1 constitutive phosphorylation is not dependent on the JAK/STAT pathway 240 
To further investigate STAT1 phosphorylation in the context of the tumor environment, we examined 241 
meningioma tumor lysates for the presence of interferon gamma (IFN) and tumor-associated 242 
Formatted: Indent: First line:  0"
NOA-D-19-00065R2 
10 
 
macrophages by using CD163 marker staining preferentially M2 macrophages 28. Variable protein 243 
levels of IFN and CD163 were detected, but there was no evident correlation with STAT1 244 
phosphorylation and no JAK1 phosphorylation was detected (Fig 2A). 245 
STAT1 usually becomes phosphorylated as a result of JAK/STAT pathway activation in response to 246 
external stimuli6. We examined whether STAT1 overexpression and phosphorylation was dependent 247 
on the culture conditions and secreted factors. Culturing HMC in serum-free (SF) media and in BM-1 248 
conditioned media, and BM-1 in SF media, we confirmed that STAT1 overexpression and 249 
phosphorylation was not due to external factors, but most likely to an intrinsic activation (Fig. 2B).  250 
 251 
Next, we decided to test the ability of the JAK/STAT pathway to respond to activating stimuli in 252 
meningioma cells. HMC and two MNs were treated with IFN; in HMC, JAK1 and JAK2 activated within 253 
10 min after treatment as well as pSTAT1-Y701 whilst pSTAT1-S727 phosphorylated within 1 h. The 254 
same behaviour was observed in MNs confirming that the JAK/STAT pathway was functional; however, 255 
STAT1 was constitutively phosphorylated in non-treated cells while pJAK1 and pJAK2 were not (Fig. 256 
2C). The same experiment, performed using interferon alpha (IFNα), produced comparable results 257 
(Supplementary Fig. 2A). 258 
After activation, pSTAT1 is known to dimerize and translocate into the nucleus6. IFN treatment was 259 
indeed able to induce pSTAT1-Y701 nuclear internalization (Fig. 2D, Supplementary Fig. 2B). Thus, 260 
the JAK/STAT1 pathway can be activated via IFN in meningioma cells but there was also an IFN-261 
independent intrinsic activation. 262 
STAT1 constitutive phosphorylations could be due to a deficient deactivation of the pathway4,5,29. Thus, 263 
we analysed the levels of the SOCSs and the PIASs in HMC, BM-1 and MN cells (Fig. 2E), which did 264 
not correlate with the constitutive phosphorylation of STAT1 observed in these samples (Fig. 1E). 265 
Overall, these data suggest that the JAK/STAT pathway is functional but not over-activated. Therefore, 266 
we hypothesized other mechanisms must be involved in maintaining STAT1 in a constitutive 267 
phosphorylated form in the meningioma samples analyzed.  268 
 269 
STAT1 overexpression is associated with an increased proliferation of meningioma cells 270 
To investigate the biological significance of STAT1 overexpression in meningioma we silenced the 271 
protein in MN cells. Lentiviral-mediated shRNA delivery into the cells produced an over 70% reduction 272 
in protein expression (Fig. 3A) and a 50% reduction in gene expression levels compared to scramble 273 
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(Fig. 3B). STAT1-silenced cells displayed a reduction in STAT1 immunofluorescent staining as well as 274 
a reduction in Ki67-positive cells (Fig. 3C). Proliferating cells were reduced from ~22% to less than 5% 275 
in MNs (Fig. 3D, E). This was in agreement with the reduction of the total number of cells (Fig. 3F) and 276 
a 40% reduction of Cyclin D1 (Fig. 3A). A similar effect was observed in BM-1 cells (Supplementary Fig. 277 
3A-D). Taken together, our results demonstrate that STAT1 overexpression is associated to an 278 
increased proliferation of meningioma tumor cells. 279 
The MAPK-ERK and the AKT pathways are known to be active in meningioma and to influence tumor 280 
progression30. After STAT1-KD, both AKT and ERK1/2 showed a 95% and 80% reduction in protein 281 
phosphorylation respectively (Fig. 3G, H), supporting a critical involvement of STAT1 in the activation 282 
of pro-proliferative pathways. 283 
 284 
Phosphorylated STAT1 affects activation of AKT and ERK1/2 and cellular proliferation 285 
We used phosphomimetics to further characterise the effects of STAT1 phosphorylation. Phenylalanine 286 
(F) and Glutamic acid (E) are used to mimic the structure of a phosphorylated tyrosine (Y) and 287 
phosphorylated serine (S) respectively31. We produced three different STAT1 mutants: Y701F, S727E 288 
and the double mutant Y701F/S727E. Since STAT1 is constitutively phosphorylated in meningioma, we 289 
used U251-MG cells as a model because this cell line showed levels of total and pSTAT1 lower than 290 
HMC (Fig. 4A). STAT1 overexpression in U251-MG for wild-type (WT) and mutants was confirmed by 291 
WB and qPCR (Fig. 4B, C). STAT1 overexpression in U251-MG cells determined an increased 292 
phosphorylation of AKT and ERK1/2, where the effect was particularly evident for pERK1/2 in STAT1-293 
S727E and STAT1-Y701F/S727E mutants (Fig. 4B). 294 
The proliferation of transfected cells was measured over a period of 72 h and normalised for the empty-295 
vector control. All STAT1 mutants showed a significantly increased proliferation rate compared to 296 
STAT1-WT; interestingly, the double mutant STAT1- Y701F/S727E, which represents STAT1 in its 297 
maximal activated condition, determined the highest pro-proliferative effect in U251-MG cells (Fig. 4B, 298 
4D).  299 
These experiments confirmed that the constitutive phosphorylation of STAT1 on both phosphosites 300 
affects the activation of the AKT and ERK1/2 pathways as well as the proliferation of the cells in 301 
agreement with STAT1 knock-down results in meningioma. 302 
 303 
EGFR constitutive phosphorylation is responsible for STAT1 overexpression and activation  304 
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It has been previously shown that STAT1 can be phosphorylated by EGFR, a key tyrosine kinase 305 
relevant to the majority of tumors32,33. We examined the EGFR status in meningioma tissues and cells, 306 
detecting high levels of pEGFR  in both tumor lysates and meningioma cells, when compared to normal 307 
meningeal tissue (NMT) and HMC (Fig. 5A). 308 
To test whether the constitutive phosphorylation of EGFR was responsible for STAT1 phosphorylation, 309 
we treated BM-1 cells with three different EGFR inhibitors (canertinib andafatinib, 2nd generation 310 
irreversible inhibitors) and erlotinib (1st generation, reversible inhibitor), , for 30 min, 3, 6 and 24 h34. . 311 
Canertinib (and similarly afatinib) decreased STAT1 expression of about 60% within 24 h upon; 312 
pSTAT1-Y701 was almost abolished 30 min after treatment but was restored at 24 h while pSTAT1-313 
S727 showed a decrease of about 90% compared to vehicle at 24 h (Fig. 5B). Almost no effect on total 314 
and pSTAT1 was detected after treatment with erlotinib, which did not cause an evident decrease in 315 
pEGFR-Y1068 after treatment (Fig. 5B).  316 
EGFR blockade via canertinib and afatinib decreased pSTAT1 levels and determined a concentration-317 
dependent decrease of cellular proliferation already at 24 h after treatment (Fig. 5C), with erlotinib being 318 
ineffective. 319 
Since canertinib showed the strongest effect on STAT1 in BM-1 cells, we tested its effects on primary 320 
MNs (Fig. 5D). Canertinib was active in reducing EGFR constitutive phosphorylation in MN cells, 321 
reducing p-STAT1 levels after canertinib treatment; pSTAT1-S727 reduced of 65% already 3 h after 322 
treatment and stayed low over the 24 h; phosphorylated STAT1-Y701 also showed about 50% reduction 323 
3 h after treatment and recovered between 6 and 24 h (Fig. 5D, E Supplementary Fig. 4). 324 
Phospho-AKT and pERK1/2 showed a decrease of about 70% and Cyclin D1 reduced t0 50% in 24 h 325 
(Fig. 5D,E,Supplementary Fig. 4). 326 
We wanted to examine whether the inhibition of pEGFR and thus of pSTAT1 had any effect on STAT1 327 
expression, as STAT1 is known to regulate its own transcription35. STAT1 expression levels reduced 328 
by ~50% 24 h after treatment with canertinib in MNs (Fig. 5F), consistently with a 30% reduction in 329 
protein level observed by WB analysis (Fig. 5D, E, Supplementary Fig. 4). 330 
Lastly, to confirm the link between EGFR activation and STAT1 phosphorylation, we treated BM-1 cells 331 
with the Epidermal Growth Factor (EGF) for 5, 30 and 60 minutes. Upon EGF treatment STAT1 was 332 
phosphorylated on Y701 within 5 minutes and on S727 within 30 minutes (Fig. 5G).   333 
Hence, we showed that EGFR is responsible for STAT1 overexpression and constitutive activation in 334 
meningioma, which consequently increases proliferation of the tumor cells.  335 
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 341 
Discussion 342 
Meningiomas are the most common primary brain tumor but there are no therapeutic options available 343 
other than surgery and radiotherapy1,36. The well-defined genetic background of meningioma is leading 344 
towards an increasing stratification of these tumors into subtypes37,38; however, common features 345 
should still be investigated. 346 
We identified STAT1 as overexpressed and activated in 84% of meningioma examined. The only 347 
study exploring the expression levels of STAT and JAK superfamilies in meningiomas was published 348 
in 1999 showing higher immunoreactivity of JAK1 (see also Supplementary Fig. 2C), JAK2 and the 349 
STATs in meningiomas compared to normal dura39. Our data confirmed the expression of the JAKs in 350 
MN cells and in HMC; we showed that the JAK/STAT pathway is activated by IFNα and IFN, inducing 351 
nuclear localization of pSTAT1 as seen before39. As previously reported40, activation of STAT1 352 
after INFγ stimulation occurs via JAK kinases by phosphorylation on Y701, resulting in 353 
pSTAT1 translocation into the nucleus and subsequent phosphorylation at S72741. Double 354 
phosphorylation is required for maximal STAT1 activity. However, we show that STAT1 is 355 
constitutively phosphorylated in MNs but not in HMC, even without IFN stimulation and in serum-free 356 
conditions. In tumor lysates, STAT1 phosphorylation was not consistent with the presence of M2-357 
polarised macrophages or IFN suggesting that the constitutive activation of STAT1 was not related to 358 
the JAK/STAT pathway. 359 
To better understand the meaning of this STAT1 phosphorylation we used phosphomimetics, 360 
generating STAT1-Y701F, STAT1-S727E and STAT1-Y701F/S727E mutants. The overexpression of 361 
these mutants induced activation of two central nodes in cancer signalling, AKT and ERK1/2, and 362 
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increased cellular proliferation. A similar approach was used on STAT3 in human prostate cancer cell, 363 
where the mutant STAT3-Y705F/S727E promoted survival, growth and invasion. They showed that the 364 
mutation S727E was increasing the transcription of c-Myc, which is an essential activator of cell growth 365 
and proliferation31. It is very likely that a similar mechanism is happening also in meningioma, where 366 
STAT1-S727 showed a predominant nuclear localization exerting its role of transcriptional regulator.  367 
We also showed the link between STAT1 overexpression and the increased proliferation of the tumor 368 
cells. This effect is most likely linked to an activating cascade involving ERK1/2 and AKT, since their 369 
activated state and cell proliferation were almost aborted after STAT1 silencing. The activation of the 370 
MAPK pathway is involved in both proliferation and apoptosis in meningioma30, and we recently 371 
published a proteomic profiling of meningioma, identifying the aberrant activation of the PI3K/AKT 372 
pathway across all meningioma grades4.  373 
Aiming to identify the kinase responsible for STAT1 activation, we examined the status of EGFR, a 374 
tyrosine kinase able to phosphorylate STAT133,42,43. EGFR was overexpressed and constitutively 375 
phosphorylated on Y1068 in all of the MN cells examined but not in HMC. To test whether EGFR 376 
phosphorylation was responsible for the constitutive activation of STAT1 we used three specific EGFR 377 
inhibitors canertinib, afatinib and erlotinib44. Whilst canertinib and afatinib, had a similar effect in 378 
reducing STAT1 phosphorylation on both phosphosites as well as on cell proliferation and viability, 379 
erlotinib, did not produce any significant effect. Interestingly this result is consistent with the 380 
unsuccessful clinical trial of erlotinib on recurrent meningiomas45. Erlotinib is a first generation ATP 381 
dependent reversible rather broad inhibitor46, Afinitinib and Canertinib are non reversible second 382 
generation with high pEC50 https://www.proteomicsdb.org/#analytics/selectivity 383 
In MN cells, canertinib (and afatinib) caused the de-phosphorylation of STAT1-Y701 and S&27 within 384 
6and 24H respectively. Similarly, EGF stimulation induces an immediate and direct phosphorylation on 385 
Y701 and a later one on S727, suggesting the activation of an additional kinase downstream of EGFR, 386 
which is probably part of the MAPK/ERK1/2 pathway47. Indeed previous studies in pancreatic cancer 387 
demonstrated the relationship between EGFR and the downstream signalling regulators like pAKT, 388 
pERK1/2 and Cyclin D133. In agreement, after canertinib treatment and after STAT1 silencing, we 389 
observed a significant reduction of pAKT and pERK1/2. Overall, levels of Cyclin D1 also displayed a 390 
significant reduction, consistently with the reduction in proliferation observed after STAT1 silencing and 391 
canertinib treatment.  392 
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The observed reduction in STAT1 expression suggest a feedback regulatory mechanism of pSTAT1 on 393 
its own promoter, already documented35, as well as an EGFR/HER2-dependent regulation as previously 394 
shown in glioblastoma and breast cancer cell lines48. 395 
In conclusion, we provide clear evidence of STAT1 overexpression in meningioma of different genotype 396 
and its correlation with an increased cellular proliferation. We demonstrate that STAT1 is aberrantly 397 
phosphorylated on both phosphosites, not because of the JAK/STAT pathway activation but because 398 
of the constitutive phosphorylation of EGFR, which elicits activation of the MAPK/ERK and PI3K/AKT 399 
pathways and an increase in the overall levels of Cyclin D1 and STAT1.  Although the whole mechanism 400 
should be additionally studied to give a thorough understanding of the activating cascade and all the 401 
partners involved in it, our studies set the basis for re-evaluating EGFR inhibition in meningioma as 402 
possible therapeutic option.  403 
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Figure Legends 533 
 534 
Fig. 1 STAT1 and its phosphorylated forms are overexpressed in meningioma. A Representative WB 535 
analysis showing the expression of total and pSTAT1 in different grade meningiomas vs. NMT  B 536 
Representative images showing the IHC staining of STAT1 and pSTAT1 in the three grades 537 
meningiomas compared to normal meninges (see black arrows) at 200X magnification. Mean scores 538 
are presented in the table below for the specimens and the normal controls examined (see also 539 
Supplementary Table 21 for the full list of specimens examined and the corresponding scores – n= 47). 540 
C STAT1 expression levels in WHO I (n= 40), WHO II (n= 25) and WHO III (n= 10) meningioma tumors 541 
normalised vs. normal meningeal tissue (NMT). Data are presented as mean  SEM; * = p≤ 0.05.  D 542 
WB showing  pSTAT1 and STAT1 in normal brain (NB) and additional normal meninges (NMT-1 and 543 
NMT-2) compared to sample J6 (meningioma) as positive control. E Representative WB analysis of 544 
STAT1 and pSTAT1 in BM-1 and in WHO I MN cells (MNs) vs. HMC. F STAT1 expression levels in 545 
BM-1 (n= 4) and in MN cells (n= 24) normalised vs. HMC. Data are presented as mean  SEM; ** = p≤ 546 
0.01. E G Confocal z-stack images showing the immunofluorescent staining of STAT1 (red) and 547 
pSTAT1 (Y701- green and S727- red) in MN cells vs. HMC. Scale bar 50 μm. Nuclei were stained with 548 
DAPI (blue).  549 
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Fig. 2 STAT1 phosphorylation in meningioma cells is not dependent on the JAK/STAT pathway. AWB 550 
of WHO I meningioma tumor tissue lysates (n= 8); the presence of gamma interferon (IFN) and 551 
macrophage infiltration (CD163) into the tumor were analysed in relation to STAT1 and pSTAT1 levels. 552 
Phospho-JAK1 was used to detect activation of the JAK-STAT pathway (*=positive control for pJAK1 553 
antibody. B). WB of total and pSTAT1 in BM-1 and HMC cells, grown in different culture condition. HMC: 554 
HMC cells media; MN: MN cells media; MN-SF: MN-serum free media; MN-SF+FBS: MN serum free 555 
for 24 h + FBS for 24h; MN Cond: meningioma cells-conditioned mediaC WB analysis of STAT1 and 556 
pSTAT1 protein levels in HMC and two primary MN cells after IFN treatment at the concentration of 50 557 
ng/ml for the indicated amount of time. Phosho-JAK1 and pJAK2 are shown to confirm the activation of 558 
the JAK/STAT pathway. D Representative confocal images (z-stack) showing localization of pSTAT1-559 
Y701 (green) and pSTAT1-S727 (red) in primary MN cells before and after IFN stimulation (50 ng/ml 560 
for 1 h). Scale bar 50 μm. Nuclei were stain with DAPI (blue). E WB analysis of SOCSs and PIASs 561 
protein levels in BM-1 and primary MNs compared to HMC.  562 
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Fig. 3 STAT1 overexpression increases meningioma cells proliferation. A Histogram representing the 563 
percentage of statistical reduction in STAT1 and Cyclin D1 protein levels after STAT1 sh-RNA-mediated 564 
silencing using a pool of three shRNA in 3 primary MN cells compared to scramble; a representative 565 
WB is shown underneath. Data are presented as mean  SD; *** = p≤ 0.001. B Percentage of reduction 566 
in STAT1 expression associated to STAT1 sh-RNA-mediated silencing compared to control shown in 567 
A; Data are presented as mean  SEM; ** = p≤ 0.01. C-D Representative images of the 568 
immunofluorescent staining of STAT1 (green) and the proliferation marker Ki67 (red) (D) after STAT1 569 
sh-RNA-mediated silencing compared to scramble. Nuclei are stain with DAPI (blue). E-F Histogram 570 
presenting the statistical reduction of proliferating cells and total number of cells (F) after STAT1-KD 571 
compared to control. Data are presented as mean  SD; *** = p≤ 0.001, ** = p≤ 0.01. G Representative 572 
WB, showing the reduction in AKT and ERK1/2 phosphorylation following STAT1 silencing. H Histogram 573 
representing the WB quantification of total and phosphorylated AKT and ERK1/2 following STAT1 574 
silencing in 3 primary MN cells, *** = p≤ 0.001, ns= not significant.  575 
  576 
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Fig. 4 STAT1 activating mutations induce phosphorylation of AKT, ERK1/2 and an increased 577 
proliferation of U251-MG cells. A WB representing total and phosphorylated STAT1 levels in U251-MG 578 
compared to HMC and BM-1 cells. B WB showing overexpression of STAT1-WT and activating mutants 579 
in U251-MG cells and the related activation of pAKT and pERK1/2. C STAT1 expression levels in U251-580 
MG cells normalised vs. STAT1 expression levels in pCDNA transfected cells (=1). Data are presented 581 
as mean  SEM; *** = p≤ 0.001. D Histogram presenting the statistical increased in cell proliferation in 582 
U251-MG cells overexpressing the activating STAT1 mutants (STAT1-Y701F, STAT1-S727E, STAT1-583 
Y701F/S727E). Data were normalised for STAT1-pCDNA-transfected cells and presented as FC of 584 
growth vs. STAT1-WT; *** = p≤ 0.001. 585 
  586 
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Fig. 5 The constitutive activation of the EGFR in meningioma induces STAT1 phosphorylation. A 587 
Representative WB analysis of total and pEGFR-Y1068 in meningioma, when compared to control. 588 
Upper panel: WHO I, II and III meningioma tissues compared to NMT; lower panel: BM-1 and primary 589 
MN cells compared to HMC. B WB of STAT1 and pSTAT1 protein levels after treatment with 5 M of 590 
canertinib, afatinib and erlotinib in BM-1 cells. The reduced levels pEGFR-Y1068 confirmed drug activity. 591 
C ATP-proliferation assay performed in BM-1 cells after treatment with different concentrations of 592 
canertininb, afatinib and erlotinib for 24 h. D WB analysis of STAT1, pSTAT1 and other markers of 593 
proliferation in primary MN cells after treatment with 10 M of canertininb. E HIistograms representing 594 
WB quantification at 3 and 24 h for STAT1, pSTAT1, pAKT, pERK 1/2 and Cyclin D1 after canertininb 595 
treatment in three different primary MN cells (see Supplementary Fig. 4). Data are presented as mean 596 
 SEM, *= p< 0.05; **= p< 0.01; ***= p< 0.001. F q-PCR analysis showing the statistical reduction of 597 
STAT1 gene expression at 3, 6 and 24 h after treatment with 10 M of canertininb (n= 3). Data are 598 
presented as mean  SEM; **= p< 0.01. G WB representing STAT1 and pSTAT1 in BM-1 cells, following 599 
treatment with EGF (50 ng/ml) for 5, 30 and 60 minutes.    600 
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Abstract 49 
Background: Meningiomas are the most frequent primary brain tumors of the central nervous system. 50 
The standard of treatment is surgery and radiotherapy, but effective pharmacological options are not 51 
available yet. The well-characterised genetic background stratifies these tumors in several subgroups, 52 
thus increasing diversification. We identified EGFR-STAT1 overexpression and activation as a common 53 
identifier of these tumors. 54 
Methods: We analysed STAT1 overexpression and phosphorylation in 131 meningiomas of different 55 
grades and locations by utilising several techniques, including Western blots, qPCR and 56 
immunocytochemistry.  We also silenced and overexpressed wild-type and mutant forms of the gene 57 
to assess its biological function and its network. Results were further validated by drug testing. 58 
Results: STAT1 was found widely overexpressed in meningioma but not in the corresponding healthy 59 
controls. The protein showed a constitutive phosphorylation not dependent on the JAK/STAT pathway.  60 
STAT1 knock-down resulted in a significant reduction of cellular proliferation and deactivation of AKT 61 
and ERK1/2. STAT1 is known to be activated by EGFR, so we investigated the tyrosine kinase and 62 
found that EGFR was also constitutively phosphorylated in meningioma and was responsible for the 63 
aberrant phosphorylation of STAT1. The pharmaceutical inhibition of EGFR caused a significant 64 
reduction in cellular proliferation and of overall levels of Cyclin D1, pAKT and pERK1/2.   65 
Conclusions: STAT1 EGFR-dependent constitutive phosphorylation is responsible for a positive 66 
feedback loop that causes its own overexpression and consequently an increased proliferation of the 67 
tumor cells. These findings provide the rationale for further studies aiming to identify effective 68 
therapeutic options in meningioma. 69 
 70 
 71 
 72 
 73 
Keywords: Meningioma, STAT1, EGFR, cancer, brain 74 
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Importance of the Study 76 
Meningioma accounts for 37% of primary brain tumors. This year in the United States an estimated 77 
thirty-two thousand people will be diagnosed with meningioma. These tumors can cause mild to severe 78 
morbidity and even WHO grade I can have a more aggressive clinical course. Therapeutic options are 79 
still limited to surgical resection and radiotherapy since more effort is needed to decipher the communal 80 
molecular mechanisms that define meningiomas despite their genetic background.  81 
Aiming to discover novel therapeutic targets, we identified STAT1 as aberrantly overexpressed and 82 
constitutively activated in most of the meningioma examined. Its activation is dependent on the 83 
constitutive phosphorylation of EGFR and leads to an increased proliferation of tumor cells. We show 84 
that specific EGFR inhibition can reduce tumor cell proliferation and we show evidence why previous 85 
trials failed. Therfore, we suggest that this therapeutic strategy be re-evaluated.  86 
 87 
  88 
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Introduction 89 
Meningiomas are the most common primary brain tumors, classified meningiomas as Grade I (~80%), 90 
atypical Grade II (15-20%) and anaplastic/malignant Grade III (1-3%). Surgery is the primary choice of 91 
treatment; complete resection may be curative but it can be achieved only for permissive locations1. 92 
The genetic background of meningioma is well characterised, with inactivation/deletion of NF2 found in 93 
~60% of sporadic meningiomas2.  94 
Previously, we identified phosphorylated Signal Transducer and Activator of Transcription 1 (STAT1) 95 
as overexpressed in the grade I meningioma cell line 3 and phosphorylated STAT1 in meningioma tissue 96 
of all grades4. In addition, we identified phosphorylation of STAT3 among remaining STAT family 97 
members3,4. STAT1 belongs to the STAT protein family that comprise seven members (STAT1-4, 98 
STAT5A, STAT5B and STAT6), and it can be phosphorylated on the tyrosine 701 (Y701) and the serine 99 
727 (S727)5,6. STATs are essential components of the evolutionarily conserved JAK/STAT signalling 100 
pathway4,7 that plays a role in immune response8,9 and its dysregulation is linked to cancer10,11. This 101 
canonical pathway is activated by ligands including interferons, interleukins and some growth factors, 102 
binding to their receptors thus inducing phosphorylation of the JAKs (Janus Kinases), leading to 103 
tyrosine-STAT phosphorylation by JAKs4,6. In addition STATs can also be phosphorylated by receptor 104 
tyrosine kinases and cytoplasmic non-receptor tyrosine kinases5. Phosphorylated STATs homo- and 105 
hetero-dimerize entering the nucleus to regulate transcription of target genes6,12. JAKs include JAK1-3 106 
and TYK2. JAK1 and JAK2 are phosphorylated following type-II interferon (IFN) stimulation, while 107 
JAK1 and TYK2 are activated in type-I interferon signalling (IFNα, IFNβ; etc.)4-6. Activated JAK/STAT 108 
pathway can be quenched by the SOCSs (Suppressors Of Cytokine Signalling), the PIASs (Protein 109 
Inhibitors of Activated STAT) and the PTPs (Protein Tyrosine Phosphatases)5 110 
Activated STAT1 acts as a transcriptional regulator, controlling its own transcription as well as the 111 
expression of several IFN-regulated genes (IRGs)13,14. STAT1 was considered a tumor suppressor as 112 
its expression correlated with good prognosis in several types of cancer15-18. However, other studies 113 
established a pro-tumorigenic role of STAT1, which correlated with its overexpression and activation19. 114 
Due to its function in sensing and regulating cytokine production, STAT1 exerts a role in promoting an 115 
immunosuppressive tumor environment19,20. Hence, the overall role of STAT1 in cancer remains 116 
complex suggesting that its function is most likely cancer type-dependent.  117 
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In the present study, we identified STAT1 as overexpressed and phosphorylated in meningioma 118 
compared to normal and we show that its overexpression correlates with an increased proliferation of 119 
the tumor cells as well as an activation of AKT and ERK1/2. We demonstrate that STAT1 120 
overexpression and phosphorylation is not dependent on the JAK/STAT pathway but it depends on a 121 
positive feedback loop caused by the constitutive activation of the Epidermal Growth Factor Receptor 122 
(EGFR). The pharmaceutical inhibition of EGFR in meningioma caused the deactivation of STAT1 and 123 
other cancer-related pathways, eventually leading to a significant reduction in cellullar proliferation. 124 
Our findings underline a crucial role of the EGFR and STAT1 signalling in the pathology of meningiomas 125 
and point to a therapeutic potential of its inhibition. 126 
 127 
Materials and Methods 128 
Meningioma specimens, tumor digestion and primary meningioma cultures 129 
Meningioma specimens were collected following the ethical approvals received a unique MN number 130 
(Supplementary Table 1). Normal meningeal tissue (NMT) was purchased from Analytical Biological 131 
Service Inc. 132 
Primary cells were generated from 36 fresh tumor tissue. Tissue were disaggregated in DMEM with 133 
15% FBS, 100 U/ml penicillin/streptomycin and 20 U/ml Collagenase III (Worthington Biochemical Corp) 134 
for 2 h at 37 C; after cells were pelleted at 1000 rpm for 5 min, resuspended and seeded (modified 135 
from21). MN cells were cultured in DMEM at 37 C in 5% CO2. HMC cells (Caltag Medsystems Ltd) 136 
were grown in the recommended medium at 37 C in 5% CO2. Cells were kept on average 4-5 137 
passages. 138 
Normal human meningeal cell were purchased from ScienceCell (UK distributor: Caltag Medsystems; 139 
Catalog#1400), U251 glioma cells were purchased from ECACC (Cat n.: 09063001), an immortalized 140 
grade 1 meningioma cell line  BM-1 were (DSMZ; Cat.n.: ACC 599) and authenticated via genomic 141 
fingerprinting (Eurofins Genomics Europe Applied Genomics GmbH).  142 
Western blotting, immunofluorescence and immunohistochemistry 143 
Western blots (WB) from 26 frozen tissues and cell cultures were performed as previously described3. 144 
All primary antibodies used are listed in Supplementary Table 2. Immunoreactive bands were quantified 145 
using Scion Image software and each band was normalized vs. the corresponding GAPDH. 146 
Immunofluorescence of 38 paraffin embedded tissue was performed as previously described3. Confocal 147 
microscopy was executed using a Leica DMI6000B; Z-stack micrographs were taken using the 40X or 148 
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63X objectives. Immunofluorescent images for STAT1-silencing studies were taken with the Olympus 149 
CKX41 with the 20X objective; images were processed with the QCapture Pro 6.0 software. 150 
For immunohistochemistry, paraffin sections (4μm) were processed as described22. Avidin-biotin 151 
blocking solution was used with EDTA pretreatment. Sections were incubated with appropriate biotin-152 
labelled secondary antibody and with horseradish peroxidase for detection using Vectashield Elite 153 
(Vector Laboratories UK) according to the manufacturer’s protocol. As a control, sections were 154 
incubated with omission of the primary antibody.  155 
Results were reviewed ‘blind’ to the histological grade by a neuropathologist (DAH). Semiquantitaive 156 
assessment of the intensity of immunoreactivity was undertaken and scored as follow: 0 none; 1 weak; 157 
2 moderate; 3 strong. 158 
RNA isolation and gene expression analysis 159 
Total RNA was extracted from 95 frozen tissues and cells using the Qiazol® reagent (Qiagen UK), 160 
following manufacturer’s protocol. The quality, integrity and concentration of RNA were established 161 
using the NanoDrop ND-2000 (ThermoFisher Scientific UK). 162 
Real-Time PCR (qPCR) was conducted using 50 ng/well employing the EXPRESS One-Step SYBR® 163 
GreenERTM kit (Invitrogen) on a LightCycler® 480 System (Roche Diagnostics, Switzerland), following 164 
manufacturer’s protocol (primers annealing temperature= 58 °C). Primers used were: PrimePCR™ 165 
SYBR® Green Assay STAT1 (BioRad), hGAPDH (2 µM, Invitrogen- Forward: 5’-166 
GAGAAGGCTGGGGCTCATTT-3’; Reverse 5’-AGTGATGGCATGGACTGTGG-3’). Relative gene 167 
expression analysis of STAT1 and GAPDH was calculated using the 2-ΔΔCt method23, employing the 168 
HMC as calibrator. 169 
STAT1 silencing and overexpression 170 
Stat1 shRNA Lentiviral Particles (Santa Cruz Biotechnology, sc-44123-V), containing 3 target-specific 171 
constructs that encode 19-25nt (plus hairpin) or scramble shRNA control (Santa Cruz Biotechnology, 172 
sc-108080), were added onto the cells in media containing protamine sulfate salt (8 μg/ ml) (Sigma). 173 
Cells were infected for 48 h before applying puromycin (5 μg/ml) for 3 days. 174 
STAT1-WT gene was cloned into pCDNA3.1+ in a two-step process using the following primers: 175 
STAT1-F1 (5’-AAAGCTAGCGGCCGGCCATGTCTCAG-3’), STAT1-R1 (5’-176 
CGTCTCGAGGTCAATTACCAAACCAGGCT-3’) for the first part; STAT1-2F (5’-177 
GACCTCGAGACGACCTCTCT), STAT1-2R (5’-AGTGTTTAAACTTAATTAACTATACTGTGTTCA-3’) 178 
for the second part. The 551 bp long STAT1 part in between the restriction sites HindIII and EcoRI was 179 
synthesised (GeneArt, ThermoFisher Scientific) to generate the following mutations: Y701F, S727E and 180 
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Y701F/S727E; each one was cloned into pCDNA-STAT1-WT to replace the wild-type part. All 181 
generated plasmids were sequenced before further use (Eurofins). U251-MG cells were transfected 182 
and selected as previously described 24. 183 
Ki-67 staining and Proliferation assay 184 
For Ki-67 staining, cells were grown on chamber slides, lentivirus-transfected and stained as previously 185 
described3.  186 
For U251-MG proliferation assay, the pool of U251-MG selected cells, transfected with pCDNA, STAT1-187 
WT and the three mutants, were seeded at 1000 cell/well in 96 well plates and proliferation was 188 
determined after 24, 48 and 72 h using the ‘CellTiter-Glo® Luminescent Cell Viability Assay’ as 189 
recommended by the supplier (Promega).  190 
For drug testing, meningioma cells (3000 cell/well) were plated in 96-well culture plates and allowed 191 
to proliferate for 24 h. Cell proliferation was calculated as percentage of control cells. Graphs were 192 
generated using GraphPad Prism 5.  193 
Flow cytometry analysis 194 
Confluent meningioma cells were resuspended in ice-cold staining buffer (PBS, 2%FBS) at a final 195 
concentration of 1x105 cells. Cells were stained for 30 min at RT in the dark with the following: CD45-196 
FITC, HLA-DR-PE, CD14-PerCP5.5 and CD44 –APC (Becton Dickinson Biosciences, Pharmigen), 197 
washed twice with 2 ml of staining buffer and centrifuged at 1500 rpm for 5 min at 4°C . The relevant 198 
single isotype controls were used. Data acquisition was collected on 1x104 cells on a Accuri  flow 199 
cytometer (BD Biosciences) and analysis was performed using the Flow Jo software v10.0  (FlowJo 200 
LLC, Ashland, OR). 201 
Statistical analysis 202 
Probability (p) values were calculated using the Student’s t-Test or the ANOVA one-way analysis of 203 
variance, using GraphPad Prism 5.01 and MS Excel 2016 software. P values <0.05 were considered 204 
statistically significant. The results are expressed as means ± SD or ± SEM. 205 
 206 
 207 
 208 
 209 
NOA-D-19-00065R2 
9 
 
 210 
Results 211 
STAT1 is overexpressed and aberrantly activated in meningioma 212 
 213 
We analysed STAT1 expression in meningioma tumors compared to normal meninges (NMT). In all 214 
cases STAT1 was overexpressed and in most of the cases, we detected high levels of  phosphorylated 215 
STAT1 (Y701 and S727) (representative Western blot of Fig. 1A and qPCR of Fig. 1C). 216 
Immunohistochemical studies validated STAT1 overexpression in all meningioma samples (Fig. 1B); 217 
also pSTAT1-Y701 and -S727 showed higher staining compared to normal meninges and an increasing 218 
score throughout the grades. As control, we further analysed STAT1 and pSTAT1 abundance in two 219 
additional normal meninges and a normal brain (Fig. 1D).  220 
Then, we examined STAT1 expression and phosphorylation in meningioma-derived primary cells (MN) 221 
and in BM-125 compared to HMC. MN cells were used between passage 3 and 5 and no B/T 222 
lymphocytes or infiltrating macrophages were detected (Supplementary Fig. 1A). All cells were  223 
vimentin-positive26 and CD90-negative, suggesting no fibroblasts contamination27 (Supplementary Fig. 224 
1B). STAT1 was found overexpressed in BM-1 and MNs compared to HMC and both pSTAT1-Y701 225 
and -S727 were present across all samples while faint and undetectable in HMC (Fig. 1C). Q-PCR 226 
analysis confirmed that STAT1 expression was higher in most of the MNs and in BM-1 compared to 227 
control (Fig. 1F). Of note, STAT1 overexpression was independent of Merlin status (Supplementary Fig. 228 
1C, D).  229 
Furthermore, pSTAT1-Y701 showed a cytoplasmic localization while pSTAT1-S727 was nuclear (Fig. 230 
1B), in agreement with the immunofluorescent staining of primary MN cells (Fig. 1G). 231 
Overall, we examined 131 meningiomas vs. 10 normal meninges and 5 normal brains and we 232 
demonstrate substantial overexpression of STAT1 in 100 of them with a variety of methods 233 
(Supplementary Table 1). 234 
 235 
STAT1 constitutive phosphorylation is not dependent on the JAK/STAT pathway 236 
To further investigate STAT1 phosphorylation in the context of the tumor environment, we examined 237 
meningioma tumor lysates for the presence of interferon gamma (IFN) and tumor-associated 238 
macrophages by using CD163 marker staining preferentially M2 macrophages 28. Variable protein 239 
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levels of IFN and CD163 were detected, but there was no evident correlation with STAT1 240 
phosphorylation and no JAK1 phosphorylation was detected (Fig 2A). 241 
STAT1 usually becomes phosphorylated as a result of JAK/STAT pathway activation in response to 242 
external stimuli6. We examined whether STAT1 overexpression and phosphorylation was dependent 243 
on the culture conditions and secreted factors. Culturing HMC in serum-free (SF) media and in BM-1 244 
conditioned media, and BM-1 in SF media, we confirmed that STAT1 overexpression and 245 
phosphorylation was not due to external factors, but most likely to an intrinsic activation (Fig. 2B).  246 
 247 
Next, we decided to test the ability of the JAK/STAT pathway to respond to activating stimuli in 248 
meningioma cells. HMC and two MNs were treated with IFN; in HMC, JAK1 and JAK2 activated within 249 
10 min after treatment as well as pSTAT1-Y701 whilst pSTAT1-S727 phosphorylated within 1 h. The 250 
same behaviour was observed in MNs confirming that the JAK/STAT pathway was functional; however, 251 
STAT1 was constitutively phosphorylated in non-treated cells while pJAK1 and pJAK2 were not (Fig. 252 
2C). The same experiment, performed using interferon alpha (IFNα), produced comparable results 253 
(Supplementary Fig. 2A). 254 
After activation, pSTAT1 is known to dimerize and translocate into the nucleus6. IFN treatment was 255 
indeed able to induce pSTAT1-Y701 nuclear internalization (Fig. 2D, Supplementary Fig. 2B). Thus, 256 
the JAK/STAT1 pathway can be activated via IFN in meningioma cells but there was also an IFN-257 
independent intrinsic activation. 258 
STAT1 constitutive phosphorylations could be due to a deficient deactivation of the pathway4,5,29. Thus, 259 
we analysed the levels of the SOCSs and the PIASs in HMC, BM-1 and MN cells (Fig. 2E), which did 260 
not correlate with the constitutive phosphorylation of STAT1 observed in these samples (Fig. 1E). 261 
Overall, these data suggest that the JAK/STAT pathway is functional but not over-activated. Therefore, 262 
we hypothesized other mechanisms must be involved in maintaining STAT1 in a constitutive 263 
phosphorylated form in the meningioma samples analyzed.  264 
 265 
STAT1 overexpression is associated with an increased proliferation of meningioma cells 266 
To investigate the biological significance of STAT1 overexpression in meningioma we silenced the 267 
protein in MN cells. Lentiviral-mediated shRNA delivery into the cells produced an over 70% reduction 268 
in protein expression (Fig. 3A) and a 50% reduction in gene expression levels compared to scramble 269 
(Fig. 3B). STAT1-silenced cells displayed a reduction in STAT1 immunofluorescent staining as well as 270 
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a reduction in Ki67-positive cells (Fig. 3C). Proliferating cells were reduced from ~22% to less than 5% 271 
in MNs (Fig. 3D, E). This was in agreement with the reduction of the total number of cells (Fig. 3F) and 272 
a 40% reduction of Cyclin D1 (Fig. 3A). A similar effect was observed in BM-1 cells (Supplementary Fig. 273 
3A-D). Taken together, our results demonstrate that STAT1 overexpression is associated to an 274 
increased proliferation of meningioma tumor cells. 275 
The MAPK-ERK and the AKT pathways are known to be active in meningioma and to influence tumor 276 
progression30. After STAT1-KD, both AKT and ERK1/2 showed a 95% and 80% reduction in protein 277 
phosphorylation respectively (Fig. 3G, H), supporting a critical involvement of STAT1 in the activation 278 
of pro-proliferative pathways. 279 
 280 
Phosphorylated STAT1 affects activation of AKT and ERK1/2 and cellular proliferation 281 
We used phosphomimetics to further characterise the effects of STAT1 phosphorylation. Phenylalanine 282 
(F) and Glutamic acid (E) are used to mimic the structure of a phosphorylated tyrosine (Y) and 283 
phosphorylated serine (S) respectively31. We produced three different STAT1 mutants: Y701F, S727E 284 
and the double mutant Y701F/S727E. Since STAT1 is constitutively phosphorylated in meningioma, we 285 
used U251-MG cells as a model because this cell line showed levels of total and pSTAT1 lower than 286 
HMC (Fig. 4A). STAT1 overexpression in U251-MG for wild-type (WT) and mutants was confirmed by 287 
WB and qPCR (Fig. 4B, C). STAT1 overexpression in U251-MG cells determined an increased 288 
phosphorylation of AKT and ERK1/2, where the effect was particularly evident for pERK1/2 in STAT1-289 
S727E and STAT1-Y701F/S727E mutants (Fig. 4B). 290 
The proliferation of transfected cells was measured over a period of 72 h and normalised for the empty-291 
vector control. All STAT1 mutants showed a significantly increased proliferation rate compared to 292 
STAT1-WT; interestingly, the double mutant STAT1- Y701F/S727E, which represents STAT1 in its 293 
maximal activated condition, determined the highest pro-proliferative effect in U251-MG cells (Fig. 4B, 294 
4D).  295 
These experiments confirmed that the constitutive phosphorylation of STAT1 on both phosphosites 296 
affects the activation of the AKT and ERK1/2 pathways as well as the proliferation of the cells in 297 
agreement with STAT1 knock-down results in meningioma. 298 
 299 
EGFR constitutive phosphorylation is responsible for STAT1 overexpression and activation  300 
It has been previously shown that STAT1 can be phosphorylated by EGFR, a key tyrosine kinase 301 
relevant to the majority of tumors32,33. We examined the EGFR status in meningioma tissues and cells, 302 
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detecting high levels of pEGFR  in both tumor lysates and meningioma cells, when compared to normal 303 
meningeal tissue (NMT) and HMC (Fig. 5A). 304 
To test whether the constitutive phosphorylation of EGFR was responsible for STAT1 phosphorylation, 305 
we treated BM-1 cells with three different EGFR inhibitors (canertinib andafatinib, 2nd generation 306 
irreversible inhibitors) and erlotinib (1st generation, reversible inhibitor), , for 30 min, 3, 6 and 24 h34. 307 
Canertinib (and similarly afatinib) decreased STAT1 expression of about 60% within 24 h upon; 308 
pSTAT1-Y701 was almost abolished 30 min after treatment but was restored at 24 h while pSTAT1-309 
S727 showed a decrease of about 90% compared to vehicle at 24 h (Fig. 5B). Almost no effect on total 310 
and pSTAT1 was detected after treatment with erlotinib, which did not cause an evident decrease in 311 
pEGFR-Y1068 after treatment (Fig. 5B).  312 
EGFR blockade via canertinib and afatinib decreased pSTAT1 levels and determined a concentration-313 
dependent decrease of cellular proliferation already at 24 h after treatment (Fig. 5C), with erlotinib being 314 
ineffective. 315 
Since canertinib showed the strongest effect on STAT1 in BM-1 cells, we tested its effects on primary 316 
MNs (Fig. 5D). Canertinib was active in reducing EGFR constitutive phosphorylation in MN cells, 317 
reducing p-STAT1 levels after canertinib treatment; pSTAT1-S727 reduced of 65% already 3 h after 318 
treatment and stayed low over the 24 h; phosphorylated STAT1-Y701 also showed about 50% reduction 319 
3 h after treatment and recovered between 6 and 24 h (Fig. 5D, E Supplementary Fig. 4). 320 
Phospho-AKT and pERK1/2 showed a decrease of about 70% and Cyclin D1 reduced t0 50% in 24 h 321 
(Fig. 5D,E,Supplementary Fig. 4). 322 
We wanted to examine whether the inhibition of pEGFR and thus of pSTAT1 had any effect on STAT1 323 
expression, as STAT1 is known to regulate its own transcription35. STAT1 expression levels reduced 324 
by ~50% 24 h after treatment with canertinib in MNs (Fig. 5F), consistently with a 30% reduction in 325 
protein level observed by WB analysis (Fig. 5D, E, Supplementary Fig. 4). 326 
Lastly, to confirm the link between EGFR activation and STAT1 phosphorylation, we treated BM-1 cells 327 
with the Epidermal Growth Factor (EGF) for 5, 30 and 60 minutes. Upon EGF treatment STAT1 was 328 
phosphorylated on Y701 within 5 minutes and on S727 within 30 minutes (Fig. 5G).   329 
Hence, we showed that EGFR is responsible for STAT1 overexpression and constitutive activation in 330 
meningioma, which consequently increases proliferation of the tumor cells.  331 
 332 
 333 
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 337 
Discussion 338 
Meningiomas are the most common primary brain tumor but there are no therapeutic options available 339 
other than surgery and radiotherapy1,36. The well-defined genetic background of meningioma is leading 340 
towards an increasing stratification of these tumors into subtypes37,38; however, common features 341 
should still be investigated. 342 
We identified STAT1 as overexpressed and activated in 84% of meningioma examined. The only 343 
study exploring the expression levels of STAT and JAK superfamilies in meningiomas was published 344 
in 1999 showing higher immunoreactivity of JAK1 (see also Supplementary Fig. 2C), JAK2 and the 345 
STATs in meningiomas compared to normal dura39. Our data confirmed the expression of the JAKs in 346 
MN cells and in HMC; we showed that the JAK/STAT pathway is activated by IFNα and IFN, inducing 347 
nuclear localization of pSTAT1 as seen before39. As previously reported40, activation of STAT1 348 
after INFγ stimulation occurs via JAK kinases by phosphorylation on Y701, resulting in 349 
pSTAT1 translocation into the nucleus and subsequent phosphorylation at S72741. Double 350 
phosphorylation is required for maximal STAT1 activity. However, we show that STAT1 is 351 
constitutively phosphorylated in MNs but not in HMC, even without IFN stimulation and in serum-free 352 
conditions. In tumor lysates, STAT1 phosphorylation was not consistent with the presence of M2-353 
polarised macrophages or IFN suggesting that the constitutive activation of STAT1 was not related to 354 
the JAK/STAT pathway. 355 
To better understand the meaning of this STAT1 phosphorylation we used phosphomimetics, 356 
generating STAT1-Y701F, STAT1-S727E and STAT1-Y701F/S727E mutants. The overexpression of 357 
these mutants induced activation of two central nodes in cancer signalling, AKT and ERK1/2, and 358 
increased cellular proliferation. A similar approach was used on STAT3 in human prostate cancer cell, 359 
where the mutant STAT3-Y705F/S727E promoted survival, growth and invasion. They showed that the 360 
mutation S727E was increasing the transcription of c-Myc, which is an essential activator of cell growth 361 
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and proliferation31. It is very likely that a similar mechanism is happening also in meningioma, where 362 
STAT1-S727 showed a predominant nuclear localization exerting its role of transcriptional regulator.  363 
We also showed the link between STAT1 overexpression and the increased proliferation of the tumor 364 
cells. This effect is most likely linked to an activating cascade involving ERK1/2 and AKT, since their 365 
activated state and cell proliferation were almost aborted after STAT1 silencing. The activation of the 366 
MAPK pathway is involved in both proliferation and apoptosis in meningioma30, and we recently 367 
published a proteomic profiling of meningioma, identifying the aberrant activation of the PI3K/AKT 368 
pathway across all meningioma grades4.  369 
Aiming to identify the kinase responsible for STAT1 activation, we examined the status of EGFR, a 370 
tyrosine kinase able to phosphorylate STAT133,42,43. EGFR was overexpressed and constitutively 371 
phosphorylated on Y1068 in all of the MN cells examined but not in HMC. To test whether EGFR 372 
phosphorylation was responsible for the constitutive activation of STAT1 we used three specific EGFR 373 
inhibitors canertinib, afatinib and erlotinib44. Whilst canertinib and afatinib, had a similar effect in 374 
reducing STAT1 phosphorylation on both phosphosites as well as on cell proliferation and viability, 375 
erlotinib, did not produce any significant effect. Interestingly this result is consistent with the 376 
unsuccessful clinical trial of erlotinib on recurrent meningiomas45. Erlotinib is a first generation ATP 377 
dependent reversible rather broad inhibitor46, Afinitinib and Canertinib are non reversible second 378 
generation with high pEC50 https://www.proteomicsdb.org/#analytics/selectivity 379 
In MN cells, canertinib (and afatinib) caused the de-phosphorylation of STAT1-Y701 and S&27 within 380 
6and 24H respectively. Similarly, EGF stimulation induces an immediate and direct phosphorylation on 381 
Y701 and a later one on S727, suggesting the activation of an additional kinase downstream of EGFR, 382 
which is probably part of the MAPK/ERK1/2 pathway47. Indeed previous studies in pancreatic cancer 383 
demonstrated the relationship between EGFR and the downstream signalling regulators like pAKT, 384 
pERK1/2 and Cyclin D133. In agreement, after canertinib treatment and after STAT1 silencing, we 385 
observed a significant reduction of pAKT and pERK1/2. Overall, levels of Cyclin D1 also displayed a 386 
significant reduction, consistently with the reduction in proliferation observed after STAT1 silencing and 387 
canertinib treatment.  388 
The observed reduction in STAT1 expression suggest a feedback regulatory mechanism of pSTAT1 on 389 
its own promoter, already documented35, as well as an EGFR/HER2-dependent regulation as previously 390 
shown in glioblastoma and breast cancer cell lines48. 391 
In conclusion, we provide clear evidence of STAT1 overexpression in meningioma of different genotype 392 
and its correlation with an increased cellular proliferation. We demonstrate that STAT1 is aberrantly 393 
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phosphorylated on both phosphosites, not because of the JAK/STAT pathway activation but because 394 
of the constitutive phosphorylation of EGFR, which elicits activation of the MAPK/ERK and PI3K/AKT 395 
pathways and an increase in the overall levels of Cyclin D1 and STAT1.  Although the whole mechanism 396 
should be additionally studied to give a thorough understanding of the activating cascade and all the 397 
partners involved in it, our studies set the basis for re-evaluating EGFR inhibition in meningioma as 398 
possible therapeutic option.  399 
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Figure Legends 529 
 530 
Fig. 1 STAT1 and its phosphorylated forms are overexpressed in meningioma. A Representative WB 531 
analysis showing the expression of total and pSTAT1 in different grade meningiomas vs. NMT  B 532 
Representative images showing the IHC staining of STAT1 and pSTAT1 in the three grades 533 
meningiomas compared to normal meninges (see black arrows) at 200X magnification. Mean scores 534 
are presented in the table below for the specimens and the normal controls examined (see also 535 
Supplementary Table 1 for the full list of specimens examined and the corresponding scores – n=47). 536 
C STAT1 expression levels in WHO I (n=40), WHO II (n=25) and WHO III (n= 10) meningioma tumors 537 
normalised vs. normal meningeal tissue (NMT). Data are presented as mean  SEM; * = p≤ 0.05.  D 538 
WB showing  pSTAT1 and STAT1 in normal brain (NB) and additional normal meninges (NMT-1 and 539 
NMT-2) compared to sample J6 (meningioma) as positive control. E Representative WB analysis of 540 
STAT1 and pSTAT1 in BM-1 and in WHO I MN cells (MNs) vs. HMC. F STAT1 expression levels in 541 
BM-1 (n=4) and in MN cells (n=24) normalised vs. HMC. Data are presented as mean  SEM; ** = p≤ 542 
0.01. E G Confocal z-stack images showing the immunofluorescent staining of STAT1 (red) and 543 
pSTAT1 (Y701- green and S727- red) in MN cells vs. HMC. Scale bar 50μm. Nuclei were stained with 544 
DAPI (blue).  545 
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Fig. 2 STAT1 phosphorylation in meningioma cells is not dependent on the JAK/STAT pathway. AWB 546 
of WHO I meningioma tumor tissue lysates (n=8); the presence of gamma interferon (IFN) and 547 
macrophage infiltration (CD163) into the tumor were analysed in relation to STAT1 and pSTAT1 levels. 548 
Phospho-JAK1 was used to detect activation of the JAK-STAT pathway (*=positive control for pJAK1 549 
antibody. B). WB of total and pSTAT1 in BM-1 and HMC cells, grown in different culture condition. HMC: 550 
HMC cells media; MN: MN cells media; MN-SF: MN-serum free media; MN-SF+FBS: MN serum free 551 
for 24 h + FBS for 24h; MN Cond: meningioma cells-conditioned mediaC WB analysis of STAT1 and 552 
pSTAT1 protein levels in HMC and two primary MN cells after IFN treatment at the concentration of 50 553 
ng/ml for the indicated amount of time. Phosho-JAK1 and pJAK2 are shown to confirm the activation of 554 
the JAK/STAT pathway. D Representative confocal images (z-stack) showing localization of pSTAT1-555 
Y701 (green) and pSTAT1-S727 (red) in primary MN cells before and after IFN stimulation (50 ng/ml 556 
for 1 h). Scale bar 50μm. Nuclei were stain with DAPI (blue). E WB analysis of SOCSs and PIASs 557 
protein levels in BM-1 and primary MNs compared to HMC.  558 
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Fig. 3 STAT1 overexpression increases meningioma cells proliferation. A Histogram representing the 559 
percentage of statistical reduction in STAT1 and Cyclin D1 protein levels after STAT1 sh-RNA-mediated 560 
silencing using a pool of three shRNA in 3 primary MN cells compared to scramble; a representative 561 
WB is shown underneath. Data are presented as mean  SD; *** = p≤ 0.001. B Percentage of reduction 562 
in STAT1 expression associated to STAT1 sh-RNA-mediated silencing compared to control shown in 563 
A; Data are presented as mean  SEM; **=p≤0.01. C-D Representative images of the 564 
immunofluorescent staining of STAT1 (green) and the proliferation marker Ki67 (red) (D) after STAT1 565 
sh-RNA-mediated silencing compared to scramble. Nuclei are stain with DAPI (blue). E-F Histogram 566 
presenting the statistical reduction of proliferating cells and total number of cells (F) after STAT1-KD 567 
compared to control. Data are presented as mean  SD; *** = p≤ 0.001, ** = p≤ 0.01. G Representative 568 
WB, showing the reduction in AKT and ERK1/2 phosphorylation following STAT1 silencing. H Histogram 569 
representing the WB quantification of total and phosphorylated AKT and ERK1/2 following STAT1 570 
silencing in 3 primary MN cells, *** = p≤ 0.001, ns= not significant.  571 
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Fig. 4 STAT1 activating mutations induce phosphorylation of AKT, ERK1/2 and an increased 573 
proliferation of U251-MG cells. A WB representing total and phosphorylated STAT1 levels in U251-MG 574 
compared to HMC and BM-1 cells. B WB showing overexpression of STAT1-WT and activating mutants 575 
in U251-MG cells and the related activation of pAKT and pERK1/2. C STAT1 expression levels in U251-576 
MG cells normalised vs. STAT1 expression levels in pCDNA transfected cells. Data are presented as 577 
mean  SEM; *** = p≤ 0.001. D Histogram presenting the statistical increased in cell proliferation in 578 
U251-MG cells overexpressing the activating STAT1 mutants (STAT1-Y701F, STAT1-S727E, STAT1-579 
Y701F/S727E). Data were normalised for STAT1-pCDNA-transfected cells and presented as FC of 580 
growth vs. STAT1-WT; *** = p≤ 0.001. 581 
  582 
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Fig. 5 The constitutive activation of the EGFR in meningioma induces STAT1 phosphorylation. A 583 
Representative WB analysis of total and pEGFR-Y1068 in meningioma, when compared to control. 584 
Upper panel: WHO I, II and III meningioma tissues compared to NMT; lower panel: BM-1 and primary 585 
MN cells compared to HMC. B WB of STAT1 and pSTAT1 protein levels after treatment with 5 M of 586 
canertinib, afatinib and erlotinib in BM-1 cells. The reduced levels pEGFR-Y1068 confirmed drug activity. 587 
C ATP-proliferation assay performed in BM-1 cells after treatment with different concentrations of 588 
canertininb, afatinib and erlotinib for 24 h. D WB analysis of STAT1, pSTAT1 and other markers of 589 
proliferation in primary MN cells after treatment with 10 M of canertininb. E Histograms representing 590 
WB quantification at 3 and 24 h for STAT1, pSTAT1, pAKT, pERK 1/2 and Cyclin D1 after canertininb 591 
treatment in three different primary MN cells (see Supplementary Fig. 4). Data are presented as mean 592 
 SEM, *= p< 0.05; **= p< 0.01; ***= p< 0.001. F q-PCR analysis showing the statistical reduction of 593 
STAT1 gene expression at 3, 6 and 24 h after treatment with 10 M of canertininb (n=3). Data are 594 
presented as mean  SEM; **= p< 0.01. G WB representing STAT1 and pSTAT1 in BM-1 cells, following 595 
treatment with EGF (50 ng/ml) for 5, 30 and 60 minutes.    596 
Supplementary Table 21. Clinical cases examined in the study.  The table provide information about all the meningiomas 
tested and the level of STAT1 overexpression (gene expression for qPCR and protein expression for WB) detected vs. 
control. , HMC=Human Meningeal Cells, L=left; R=right; n/a= not available; M=male; F=female,  WB= Western Blot; qPCR= 
quantitative Polymerase Chain Reaction; IF= immunofluorescence; IHC= immunohistochemistry; Control (STAT1 expression 
= 1); ~ = STAT1 expression below 2; + = 2/3 times STAT1 overexpression; ++ = 5/6 times STAT1 overexpression; +++ = ≥ 
10 times STAT1 overexpression.  
ID Type, Location           WHO        Gender 
Age of 
diagnosis 
      Analysis        STAT1 
Ben Men-1 cells Benign meningioma cell line I F 68 WB, qPCR, IF + 
BTNW71 tissue Anaplastic, L posterior fossa  III F 70 qPCR ++ 
BTNW162 tissue Anaplastic, L fronatl III F 76 qPCR ++ 
BTNW811 tissue Anaplastic, L posterior fossa III F 64 qPCR ++ 
BTNW831 tissue Anaplastic frontal III F 68 qPCR ++ 
BTNW1456 tissue Anaplastic, L frontal III M 48  qPCR + 
MN001 tissue Atypical, R frontal  II M 50 IHC, qPCR + 
MN005 cells Fibroblastic, L posterior fossa I F 59 IHC, qPCR ++ 
MN015 cells Psammomatous, cervical  I F 61 WB, qPCR + 
MN017 cells Transitional, frontal convexity I F 51 WB, qPCR, IF + 
MN020 tissue Atypical, R parietal II F 39 qPCR ~ 
MN023 cells Meningothelial, L parietal convexity I M 63 WB, qPCR +++ 
MN028 cells Transitional, cervical I F 63 WB, qPCR, IF ++ 
MN031 cells Psammomatous, thoracic I F 72 WB, qPCR, IF ++ 
MN033 cells Transitional,  anterior skull base 
basewith rosettes, cranial fossa 
I F 65 WB, qPCR, IF + 
MN036 cells n/a, R CPA I F 51 WB, qPCR ++ 
MN038 cells Transitional, L parietal I F 79 qPCR +++ 
MN045 tissue Atypical, extra axial parietal II M n/a qPCR ~ 
MN048 cells Fibroblastic, L parietal I F 57 WB, qPCR +++ 
MN052 cells Psammomatous, R frontal 
parafalcine 
I F 70 qPCR ++ 
MN054 tissue n/a, R posterior sinus I F 58 qPCR ~ 
MN055 tissue n/a, L frontal I F 50 qPCR ~ 
MN056 cells n/a, R posterior fossa I F 61 qPCR ++ 
MN057 cells Meningothelial, L parietal I M 58 qPCR +++ 
MN058 tissue Angiomatous, RT frontal I F 65 qPCR ~ 
MN062 cells Meningothelial, olfactory groove I F 43 qPCR ++ 
MN066 cells Psammomatous, thoracicvertebral 
column 
I M 83 qPCR ++ 
MN071 cells Secretory/angiomatous, R petroclival 
ppetrocicpetroclivalpetroclival 
I F 52 qPCR ++ 
MN073 cells Fibroblastic, L onvexity I F 70 qPCR ++ 
MN074 cells Transitional, R angular gyrus I F 37 qPCR + 
MN075 tissue/cells Transitional, RT parietal I F 79 qPCR ~ 
MN076 tissue/cells Atypical, olfactory groove II F 53 WB, qPCR +++ 
MN077 cells Transitional, bilateral parasagittal I F 66 qPCR +++ 
MN078 cells Transitional, L frontal I M 70 qPCR +++ 
MN079 tissue/cells Atypical, occipital II M 75 qPCR ~ 
MN080 cells Fibrous, L petrous  I F 64 WB, qPCR +++ 
MN082 cells Fibroblastic, R tentorial I F 57 qPCR +++ 
MN085 cells Psammomatous/  fibrous, L frontal 
 L frontal 
I F 56 qPCR +++ 
MN087 tissue n/a, CPA I M 47 qPCR ~ 
MN088 tissue Transitional, sphenoid wing I F n/a qPCR ~ 
MN089 cells Transitional, L parasagittal I M 53 qPCR +++ 
MN091 cells n/a, L sphenoid wing I F 62 qPCR +++ 
MN092 cells Microcystic, R convexity I F 59 qPCR +++ 
MN097 tissue Atypical, L parasagittal recurrent II F 66 WB, qPCR +++ 
MN101 tissue Atypical, RT frontal II F 51 qPCR ++ 
MN102 cells n/a, L frontal convexity I F 56 qPCR +++ 
MN104 tissue Atypical, RT paracentral II F 37 qPCR ~ 
MN105 tissue Atypical, RT frontal II F n/a qPCR ~ 
MN106 cells Psammomatous, planum sphenoid 
sphnoidspheroidale 
I F 46 qPCR + 
MN107 cells Tra sitional , R sphenoid wing I M 77 qPCR +++ 
MN109 cells Transitional, L posterior frontal I F 48 qPCR +++ 
MN110 cells Transitional, L lateral ventricle I F 47 qPCR ++ 
MN113 cells Secretory, R temporal I F 52 qPCR +++ 
MN114 cells Meningothelial, L parasagittal 
convexity 
I M 62 qPCR +++ 
MN115 tissue Larg  cystic falcine I M 69 qPCR + 
MN125 tissue Secretory, Left petroclival I F 63 qPCR +++ 
MN133 tissue Meningothelial, R fronto-parietal I M 87 WB ++ 
MN139 tissue Transitional, R sphenoid wing I n/a n/a qPCR + 
MN140 tissue n/a, Transitional I M 74 qPCR ++ 
MN148 tissue Atypical, RT frontal II M 79 qPCR ~ 
MN149 tissue Meningothelial, R frontal I n/a n/a qPCR ~ 
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Age of 
diagnosis 
      Analysis        STAT1 
MN157 tissue Meningothelial,extrafrontal 
axialfrontal 
I F n/a qPCR ~ 
MN168 tissue Atypica, RT frontal-occipital II n/a n/a qPCR + 
MN170 tissue Meningothelial, frontal parafalcine I F 70 WB, qPCR + 
MN176 tissue Microcystic, L frontal convexity I F 43 WB ~ 
MN180 tissue Transitional, R occipital lobe I F 45 WB, qPCR ++ 
MN182 tissue Atypical, RT fronto-parietal II F 66 qPCR ~ 
MN183 tissue Chordoid, sellar region II F 75 qPCR ~ 
MN186 tissue Anaplastic, R temporal III M 62 qPCR ~ 
MN188 tissue Fibrous, poster fossa I F 33 qPCR ~ 
MN189 tissue Atypical, left lateral ventricle II M 55 qPCR ++ 
MN194 tissue Atypical, occipital II F 41 qPCR ~ 
MN196 tissue Atypical, L parafalcine II M 39 qPCR ~ 
MN200 tissue Atypical, L fronto-parietal II n/a 66 qPCR +++ 
MN2078 tissue Psammomatous, thoracic 
vspinespie 
I F n/a qPCR ~ 
MN214 tissue Meningothelial, olfactory groove I F n/a qPCR ~ 
MN217 tissue Fibrous, R tentorial I n/a n/a qPCR ++ 
MN219 tissue Atypical, L fronto-parafalcine II M 55 qPCR ~ 
MN225 tissue Atypical, L fronto-parafalcine II M 57 qPCR ~ 
MN234 tissue Atypical, R fronto-parietal II F 79 qPCR + 
MN235 tissue Atypical, R fronto-parafalcine II F 71 qPCR ~ 
MN242 tissue Fibrous, olfactory groove I F n/a qPCR ~ 
MN248 tissue MixedTransitional, frontal I M n/a qPCR + 
MN251 tissue Fibrous, tentorial I F n/a qPCR ~ 
MN252 tissue Atypical, R parasagittal II F 73 qPCR ~ 
MN261 tissue Transitional, L parasagittal I M n/a qPCR + 
MN263 tissue Atypical, L frontal convexity II M 78 qPCR ~ 
MN274 tissue Fibrous, L parietal I F 68 qPCR +++ 
MN278 tissue Meningothelial, R sphenoid  
sssphemnoid 
I F n/a qPCR + 
MN332 tissue L frontal parafalcine II M 68 qPCR ~ 
MN338 tissue L temporal convexity II F 88 qPCR ++ 
NH09 tissue MalignantAnaplastic, occipital III n/a n/a qPCR +++ 
NH10 tissue MalignantAnaplastic, frontal III n/a n/a qPCR +++ 
J1 tissue Atypical, sphenoid wing II F 62 IHC ++ 
J2 tissue Atypical, parafalcine II F 51 WB, IHC ++ 
J3 tissue Atypical, frontal II M 64 WB, IHC ++ 
J4 tissue Atypical brain invasion, occipital II M 66 WB, IHC, qPCR +++ 
J5 tissue Fibroblastic, occipital  I F 50 WB, IHC +++ 
J6 tissue Transitional, parasagittal I F 37 WB, IHC +++ 
J7 tissue Transitional, parasagittal I F 72 WB, IHC +++ 
J8 tissue Transitional, parasagittal I F 68 WB, IHC ++ 
J9 tissue Malignant, occipital III F 82 WB, IHC ++ 
J10 tissue Malignant occipital III M 85 WB, IHC, qPCR ++ 
J11 tissue Malignant, occipital III M 85 WB, IHC, qPCR +++ 
J12 tissue Malignant, parasagittal III M 87 WB, IHC ++ 
J22 tissue Atypical, occipital II M 69 qPCR ++ 
J23 tissue Atypical, temporal II F 62 qPCR ++ 
nD1 tissue/a Meningothelial I n/a n/a IHC + 
n/aD2 tissue Meningothelial I n/a n/a IHC + 
n/aD3 tissue Meningothelial I n/a n/a IHC + 
n/aD4 tissue Secretory I n/a n/a IHC +++ 
n/aD5 tissue Secretory I n/a n/a IHC +++ 
n/aD6 tissue Secretory I n/a n/a IHC ++ 
n/aD7 tissue Secretory I n/a n/a IHC +++ 
D8 tissuen/a Secretory I n/a n/a IHC +++ 
D9 tissuen/a Secretory I n/a n/a IHC + 
D10 tissuen/a Transitional I n/a n/a IHC ++ 
D11 tissuen/a Mosaic Fibroblastic I n/a n/a IHC + 
D12 tissuen/a Fibroblastic I n/a n/a IHC ++ 
D13 tissuen/a Fibroblastic I n/a n/a IHC ++ 
D14 tissuen/a Psammomatous, spinal I n/a n/a IHC ++ 
D15 tissuen/a Atypical II n/a n/a IHC ++ 
D16 tissuen/a Atypical II n/a n/a IHC ++ 
D17 tissuen/a Atypical, brain invasion II n/a n/a IHC ++ 
D18 tissuen/a Atypical, brain invasion II n/a n/a IHC ++ 
D19 tissuen/a Atypical, brain invasion II n/a n/a IHC ++ 
D20 tissuen/a Malignant III n/a n/a IHC ++ 
D21 tissuen/a Malignant III n/a n/a IHC + 
D22 tissuen/a Malignant III n/a n/a IHC + 
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D23 tissuen/a Malignant III n/a n/a IHC +++ 
D24 tissuen/a Malignant III n/a n/a IHC ++ 
D25 tissuen/a Malignant III n/a n/a IHC +++ 
HMC Human meningeal cells n/a n/a n/a WB, qPCR, IF Control 
BioChainR1234043-10 Cerebral meninges  n/a F 82 WB, qPCR Control 
ABS150102416 Cerebral meninges n/a F 92 WB, qPCR Control 
ABS60200003215 Cerebral meninges n/a F 78 WB, qPCR Control 
n/aC1 Cerebral meninges n/a n/a n/a IHC Control 
n/aC2 Cerebral meninges n/a n/a n/a IHC Control 
n/aC3 Cerebral meninges n/a n/a n/a IHC Control 
n/C4a Cerebral meninges- glioma n/a n/a n/a IHC Control 
n/C5a Cerebral meninges- glioma n/a n/a n/a IHC Control 
n/C6a Cerebral meninges- glioma n/a n/a n/a IHC Control 
Abcamab29466 Brain (human) tissue lysate n/a n/a n/a WB + 
n/C7a Normal brain temporal lobe n/a n/a n/a IHC Control 
n/C8a Normal brain temporal lobe n/a n/a n/a IHC + 
n/C9a Normal brain occipital lobe n/a n/a n/a IHC Control 
n/C10a Normal brain frontal lobe n/a n/a n/a IHC Control 
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Supplementary Table 12. Complete list of the antibodies employed in the study, their application and 
the concentrations used. WB: Western Blot; IF: Immunofluorescence; IP: Immunoprecipitation; IHC: 
Immunohistochemistry. 
 
 
Antibody Manufacturer Application Dilution 
STAT1 Cell Signaling Technology - #9172 
Santa Cruz Biotechnology - sc-592 
WB 
WB 
IF 
IHC 
1:1000 
1:1000 
1:300 
1:150 
pSTAT1-Y701 Abcam - ab29045 
 
R&D Systems - AF2894 
 
Cell signalling - #7649 
WB 
IF 
WB 
IHC 
WB 
IP 
1:500 
1:100 
1:1000 
1:200 
1:500   
1:50 
pSTAT1-S727 Cell Signaling Technology - #9177 
 
WB 
IF 
IHC 
1:1000 
1:100 
1:400 
JAK1 Cell Signaling Technology - #3344 WB 1:1000 
pJAK1- Y1022/1023 Cell Signaling Technology - #3331 WB 1:500 
JAK2 Cell Signaling Technology - #3230 WB 1:1000 
pJAK2- Y1007/1008 Cell Signaling Technology - #3771 WB 1:500 
TYK2 Cell Signaling Technology - #14193 WB 1:500 
pTYK2- Y1054/1055 Cell Signaling Technology - #9321 WB 1:500 
IFN  Abcam - ab25101 WB 1:500 
CD163 Bio-Rad - MCA1853 WB 1:500 
Merlin Cell Signaling Technology - #6995 WB 1:1000 
pMerlin- S518 Cell Signaling Technology - #9163 WB 1:500 
ERK Cell Signaling Technology - #4695 WB 1:2000 
pERK- T202/204 BD Biosciences - #612358 WB 1:500 
AKT1 Cell Signaling Technology - #4691 WB 1:1000 
pAKT1- S473 Cell Signaling Technology - #9271 WB 1:500 
RB Cell Signaling Technology - #9309 WB 1:2000 
pRB- S780 Cell Signaling Technology - #8180 WB 1:1000 
CD63 (MEM-259) Thermo Fisher Scientific - MA119281 IF 1:250 
CD63 Cambridge Bioscience - EXOAB-CD63A-1 WB 1:500 
CD9 (C-4) Santa Cruz Biotechnology - #13118 IF 1:250 
CD9 Cell Signaling Technology - #13174 WB 1:500 
GM130 BD Transduction Laboratories - #610823 WB 1:1000 
Calnexin (H-70) SantaCruz Biotechnology - #11397 WB 1:1000 
CyclinD1 Cell Signaling Technology - #2978 WB 1: 300 
Ki67 (MIB-1) DAKO - #M7240 IF 1: 1000 
PIAS1 Cell Signaling Technology - #3550 WB 1:1000 
PIAS3 Cell Signaling Technology - #9042 WB 1:1000 
PIAS4 Cell Signaling Technology - #4392 WB 1:1000 
SOCS1 Cell Signaling Technology - #3950 WB 1:1000 
SOCS2 Cell Signaling Technology - #2779 WB 1:1000 
SOCS3 Cell Signaling Technology - #2932 WB 1:1000 
EGFR Cell Signaling Technology - #4267 WB 1:1000 
pEGFR- Y1068 Cell Signaling Technology - #3777 WB 1:500 
pP70 S6K – T421/S424 Cell Signaling Technology - #9204 WB 1:500 
P70 S6K Cell Signaling Technology - #9202 WB 1:500 
GAPDH EMD Millipore – MAB374 WB 1:50000 
Table Click here to access/download;Table;Supplementary
Table2_NOAR2.docx
Figure Click here to access/download;Figure;Figure 1 NOA_revised.tif
Figure Click here to access/download;Figure;Figure 2 NOA_revised.tiff
Figure Click here to access/download;Figure;Figure 3 NOA_revised.tiff
Figure Click here to access/download;Figure;Figure 4 NOA_revised.tiff
Figure Click here to access/download;Figure;Figure 5 NOA_revised.tiff
Supplementary File
Supplementary File
Supplementary File
Supplementary File
1 
 
Supplementary Figure Legends 1 
 2 
Supplementary Fig. 1 Purity of primary meningioma cultures and genetic background of our cohort of samples. 3 
A Representative flow cytometry analysis of primary MN cells. Dot plots show 10,000 live cells and represent  4 
monocyte marker, CD14-PerCP-Cy5.5 (FL3 channel) and potential meningioma tumour marker, CD44-APC (FL4 5 
channel). Upper right quadrant represents CD14+ CD44+ phenotype and decreases with passage number (CD14+ 6 
CD44+ % = Passage 0-4.6, Passage 1-2.1, Passage 2-0.1, Passage 3-0.2). Data analysed was performed on Flow 7 
Jo version10.0. B Representative confocal images of three primary MN cells tested at passage 3, homogeneously 8 
positive for the meningioma marker vimentin (green), while negative for the fibroblast marker CD90. Scale bar 9 
10 μm. Nuclei were stain with DAPI (blue). C WB analysis showing the expression of Merlin in different grade 10 
meningiomas vs. NMT; Next Generation Sequencing (NGS) confirmed that only samples J8, J1 and J2 were 11 
Merlin-positive not having any mutation on Merlin or loss of heterozygosity (LOH). D WB showing the expression 12 
of Merlin in in BM-1 and tumour-derived MN cells vs. HMC.  13 
Supplementary File
2 
 
Supplementary Fig. 2 The JAK/STAT pathway in meningioma cells can be activated by IFNα. A WB analysis of 14 
STAT1 and pSTAT1 (Y701 and S727) protein levels in HMC and two primary MN cells, after IFNα treatment at the 15 
concentration of 50 ng/ml for the indicated amount of time. Phosho-JAK1 and pTYK2 are shown to confirm the 16 
activation of the JAK/STAT pathway. B Representative confocal z-stack images showing localization of pSTAT1-17 
Y701 (green) and pSTAT1-S727 (red) in primary MN cells before and after IFNα stimulation (50 ng/ml for 1 h). 18 
Scale bar 50 μm. Nuclei were stain with DAPI (blue). C Representative WB conducted in primary MN cells showing 19 
higher levels of JAK1, when compared to HMC.   20 
3 
 
Supplementary Fig. 3 STAT1 knocked-down reduces proliferation of BM-1 meningioma cells. A WB analysis 21 
showing the reduction in STAT1 protein levels after STAT1 sh-RNA-mediated silencing compared to scramble 22 
control. B Reduction in STAT1 gene expression associated to STAT1 sh-RNA-mediated silencing compared to 23 
scramble control. Data are presented as mean  SEM; * = p≤ 0.05. C Representative images of the 24 
immunofluorescent staining of STAT1 (green) and the proliferation marker Ki67 (red) after STAT1 sh-RNA-25 
mediated silencing compared to scramble control. Nuclei are stain with DAPI (blue). D Histogram presenting the 26 
statistical reduction of proliferating cells after STAT1-KD compared to scramble control. Data are presented as 27 
mean  SD; * = p≤ 0.05.  28 
4 
 
Supplementary Fig. 4 WB quantification after canertinib treatment in primary MN cells. Detailed WB 29 
quantification for the histograms presented in Fig 5E. Protein expression was quantified after 30 
normalising for the corresponding GAPDH amount and is presented as fold change of the vehicle-31 
treated sample (V). 32 
 33 
